Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Egis Pharmaceuticals PLC","sponsor":"Crescita Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$0.7 million","newsHeadline":"Crescita Signs Exclusive 8-Country Licensing Agreement with Egis Pharmaceuticals for Pliaglis\u00ae","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"HUNGARY","productType":"Small molecule","productStatus":"Approved","date":"December 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Egis Pharmaceuticals PLC","sponsor":"National Institute of Pharmacy and Nutrition","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Egis Favipiravir Drug Licenced for Covid-19 Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"HUNGARY","productType":"Small molecule","productStatus":"Approved","date":"December 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals by Egis Pharmaceuticals PLC

    Menu

    Egis Pharmaceuticals PLC

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    Key Products KEY PRODUCTS

    SERVICES

    Key Services KEY SERVICES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Egis Pharmaceuticals PLC

              Contact Supplier
              • Deals
              Virtual BoothEgis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.
              Contact Supplier Contact Supplier
              Flag Hungary
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Crescita Signs Exclusive 8-Country Licensing Agreement with Egis Pharmaceuticals for Pliaglis®

              Details:

              The formulation contains a eutectic mixture of 7% lidocaine and 7% tetracaine that utilizes phase-changing topical cream Peel technology. In clinical studies, the mean duration of anesthesia has been shown to be in the range of 7 to 9 hours after the application of Pliaglis.

              Lead Product(s): Lidocaine,Tetracaine

              Therapeutic Area: Neurology Product Name: Pliaglis

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: Crescita Therapeutics

              Deal Size: Undisclosed Upfront Cash: $0.7 million

              Deal Type: Licensing Agreement December 13, 2021

              Egis Pharmaceuticals

              euroPLX Dublin

              Attending

              envelop Contact Supplier

              Egis Pharmaceuticals PLC

              Contact Supplier
              • Development Update
              Virtual BoothEgis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.
              Contact Supplier Contact Supplier
              Flag Hungary
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Egis Favipiravir Drug Licenced for Covid-19 Treatment

              Details:

              The active ingredient favipiravir manufactured by Hungarian pharmaceutical company Egis has been licenced for treatment of Covid-19 by the National Institute of Pharmacy and Nutrition (OGYÉI).

              Lead Product(s): Favipiravir

              Therapeutic Area: Infections and Infectious Diseases Product Name: Favipiravir-Generic

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: National Institute of Pharmacy and Nutrition

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 20, 2020

              Egis Pharmaceuticals

              euroPLX Dublin

              Attending

              envelop Contact Supplier

              Egis Pharmaceuticals
              Send me more info on How To Grow My Business Digitally?
              Post Enquiry
              POST ENQUIRY